Gregory N
Department of Dermatology, Albany Medical College, New York, USA.
J Am Acad Dermatol. 1996 Sep;35(3 Pt 2):S13-6. doi: 10.1016/s0190-9622(96)90064-x.
Superficial fungal infections, including onychomycosis, have become an increasing problem as the number of patients with HIV infection or AIDS has grown. Superficial fungal infections and other cutaneous and noncutaneous disorders are correlated with a decline in the patient's CD4 cell count and are markers of disease progression. For those HIV-positive patients with fungal nail infections, the introduction of the new triazole antifungal agents (e.g., itraconazole, fluconazole) has markedly improved the therapeutic outcome. Unlike traditional topical or oral antifungal therapies, whose clinical utility was limited by relatively poor efficacy and the need for prolonged treatment, the new triazoles fulfill one of the foremost goals of HIV-infected patients: rapid symptomatic improvement of onychomycosis. For many patients, particularly those who live in areas with a high incidence of HIV, the psychologic rewards associated with the alleviation of this unsightly and "telltale" condition are immeasurable.
随着感染HIV或患艾滋病的患者数量增加，包括甲癣在内的浅表真菌感染问题日益严重。浅表真菌感染以及其他皮肤和非皮肤疾病与患者CD4细胞计数下降相关，是疾病进展的标志。对于那些患有真菌性甲感染的HIV阳性患者，新型三唑类抗真菌药物（如伊曲康唑、氟康唑）的引入显著改善了治疗效果。与传统的局部或口服抗真菌疗法不同，传统疗法的临床效用因疗效相对较差和需要长期治疗而受到限制，新型三唑类药物实现了HIV感染患者的首要目标之一：迅速改善甲癣的症状。对于许多患者，尤其是那些生活在HIV高发地区的患者，缓解这种难看且“暴露病情”的状况所带来的心理回报是无法估量的。
